BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zinlirvimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zinlirvimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07054931-982@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Zinlirvimab: Phase 2 readout est. (NCT07054931)
DESCRIPTION:Zinlirvimab\, phase 2\, HIV.\nStudy: Combination Vaccination an
 d Broadly Neutralising Antibody Therapy in HIV\nEstimated primary completi
 on: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zinlirvimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07054931
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-982@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zinlirvimab: Phase 3 readout est. (NCT07683000)
DESCRIPTION:Zinlirvimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 o
 n Stable Oral Treatment Regimens\nEstimated primary completion: March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zinlirvimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07683000
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-982@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zinlirvimab: Phase 3 readout est. (NCT07682961)
DESCRIPTION:Zinlirvimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologi
 cally Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy\nE
 stimated primary completion: March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zinlirvimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
